Lenalidomide - ALZFORUM Lenalidomide is structurally similar to thalidomide, and as such is considered a teratogen with the potential to cause birth defects and fetal death Lenalidomide is being pursued as an alternative to thalidomide, whose development for AD was stopped because of dose-limiting toxicity in elderly patients (Decourt et al , 2017)
Therapeutics | ALZFORUM AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
Getting to First BACE: BACE1 Inhibition Takes a Step Forward Because the immunomodulatory drug thalidomide is known to inhibit TNF signaling, Shen and colleagues tested thalidomide’s effects in mice, and confirmed that it reduced Aβ levels and plaque numbers